ArticleESMO open2020
Molecular profile of BRCA-mutated biliary tract cancers.
Article in ESMO open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Pooled it
- A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Trial
- Prognostic, Predictive, and Clinical Relevance of DNA Damage Repair Alterations in Biliary Tract Cancers.Cancers · 2026Review
- Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis.EBioMedicine · 2026Article
- Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026Review
- Hyponatremia predicts immunotherapy resistance in biliary tract cancer.Human vaccines & immunotherapeutics · 2025Article
- Chronic Liver Disease Associated Cholangiocarcinoma: Genomic Insights and Precision Therapeutic Strategies.Cancers · 2025Review
- Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies.International journal of clinical oncology · 2025Review
- Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies.Frontiers in immunology · 2025Review
- Biliary tract cancers: advances in diagnostic and management.Exploration of targeted anti-tumor therapy · 2025Review
- Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer.Current treatment options in oncology · 2024Review
- Article
- Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies.Biomarkers in medicine · 2024Review
- Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma.Current treatment options in oncology · 2024Review
- How to incorporate new agents into precise medicine for cholangiocarcinoma?American journal of cancer research · 2024Review
- Perioperative and palliative systemic treatments for biliary tract cancer.Therapeutic advances in medical oncology · 2024Review
- Establishment and characterization of a novel hilar cholangiocarcinoma cell line, CBC3T-1.Human cell · 2024Article
- Durable response to first-line PARP inhibition inJournal of gastrointestinal oncology · 2023Article
- Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments.Cancers · 2023Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
22 authors at 14 institutions in 3 countries.
Funding
Abstract
introductionPrognosis of biliary tract cancers (BTC) remains dismal and novel treatment strategies are needed to improve survival. MATERIAL AND
methodsTumour samples from 1292 patients with BTC, comprising intrahepatic cholangiocarcinoma (IHC, n=746), extrahepatic cholangiocarcinoma (EHC, n=189) and gallbladder cancer (GBC, n=353), were analysed using next-generation sequencing (NGS). Tumour mutational burden (TMB) was calculated based on somatic non-synonymous missense mutations. Determination of tumour mismatch repair (MMR) or microsatellite instability (MSI) status was done by fragment analysis, immunohistochemistry and the evaluation of known microsatellite loci by NGS. Programmed death ligand 1 expression was analysed using immunohistochemistry.
resultsOverall,
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.